Overview of the biopharmaceutical moieties, developed with technology from the Protein Technologies consortium, in (pre)clinical development or marketed.

Spin-off company: Animab

F4+ ETEC targeting VHH & IgA-Fc -fusion antibody 

An oral feed-based passive immunization strategy against a pathogen (ETEC) causing post-weaning infections in young piglets. Technology built on the cross-disciplinary research and expertise within the labs of Henri De Greve (VIB/VUB), Ann De Picker (VIB/UGent) and Nico Callewaert (VIB/UGent) as well as the lab of Eric Cox from the veterinary faculty of UGent.  Read all about it in the 2019 Nature Biotechnology paper or on the spin-off company's website (Animab).

animab logo.png

Spin-off company: Exevir


The lab of Xavier Saelens (VIB-UGent Center for Medical Biotechnology) has announced the isolation and characterization of a unique antibody that can bind to the virus that causes COVID-19 (SARS-CoV-2). The team has established that the antibody binds to the spike protein of SARS-CoV-2. Importantly, the antibody can neutralize a lab variant of the virus. Their work appears in Cell. The researchers are also developing a mouse model for assessing COVID-19 antibody and vaccine candidates. In 2020, a spin-off company, Exevir, was created to further develop a therapeutic antibody against SARS-CoV-2.



Enzybiotics are a new breed of antimicrobials. They can be functionally optimized using a modular design- and synthesis approach. The VersaTile platform uses this specific approach for neofunctionalization of proteins to create other, new biopharmaceutical molecules. Read more in this Science Advances paper.